[{"id":"66bbc355-4d43-4f86-b202-dae1ff4f4602","acronym":"","url":"https://clinicaltrials.gov/study/NCT02628613","created_at":"2021-01-18T12:46:44.663Z","updated_at":"2024-07-02T16:36:54.057Z","phase":"Phase 2","brief_title":"Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations","source_id_and_acronym":"NCT02628613","lead_sponsor":"Fudan University","biomarkers":" HER-2 • TEKT4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • TEKT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • epirubicin • vinorelbine tartrate"],"overall_status":"Completed","enrollment":" Enrollment 91","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2019-11-01"}]